Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 03, 2018 08:00 ET | Source: Immutep Limited

Progress Towards Clinical Development of IMP761 – a LAG-3 Agonist Antibody

SYDNEY, Australia, Sept. 03, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep”, the “Company”), a biotechnology company developing novel immunotherapy treatments for...
August 21, 2018 04:44 ET | Source: Immutep Limited

Immutep Receives A$1.9 Million Research and Development Related Tax Rebate from French Government

SYDNEY, Australia, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
August 16, 2018 08:00 ET | Source: Immutep Limited

Immutep to Present at the BioCentury 25th Annual NewsMakers in the Biotech Industry Conference

SYDNEY, Australia, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for...
August 07, 2018 08:00 ET | Source: Immutep Limited

TACTI-mel Patient Recruitment Complete and Operational Update

Patient recruitment completed for Part B of ongoing TACTI-mel Phase I clinical trialProgress on Immutep’s TACTI-002 and AIPAC GSK nominates ulcerative colitis as its lead indication for IMP731...
July 30, 2018 21:37 ET | Source: Immutep Limited

Immutep’s LAG-3 Immunostimulant Product Candidate, Efti, Receives IND Approval From U.S. FDA

On schedule to initiate the TACTI-002 Phase II clinical study in 2H 2018 SYDNEY, Australia, July 30, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”)...
July 02, 2018 08:00 ET | Source: Immutep Limited

Immutep Submits Investigational New Drug (IND) Application With FDA

SYDNEY, Australia, July 02, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (“Immutep” or “the Company”) is pleased to announce that it has submitted its Investigational New Drug...
May 30, 2018 08:00 ET | Source: Immutep Limited

Positive New Data from Ongoing TACTI-mel Study in Unresectable or Metastatic Melanoma Presented in Global Webcast

New data presented shows ORR of 61% (11/18 patients) SYDNEY, Australia, May 30, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) ("Immutep“ or “the Company“), a biotechnology...
May 17, 2018 08:00 ET | Source: Immutep Limited

Immutep to Present Interim Results from TACTI-mel Clinical Trial in Global Webcast

Chief Medical Officer Dr. Frederic Triebel to Present at the 3rd Annual Advances in Immuno-Oncology Congress SYDNEY, Australia, May 17, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM)...
May 04, 2018 04:00 ET | Source: Immutep Limited

Immutep to Present at 2018 ASCO Annual Meeting

SYDNEY, Australia, May 04, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (Immutep or the Company) today announced that it will present posters during the 2018 American Society for...
April 12, 2018 21:24 ET | Source: Immutep Limited

Immutep Completes A$6.31 Million Share Purchase Plan; Raises Total of A$13.16 Million

SYDNEY, Australia, April 12, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (“Immutep” or the “Company”) advises that its Share Purchase Plan (“SPP”) closed as planned on 6 April...